ADA Scientific Sessions 2025 Abstract

Insights from 1,062 Clinicians—Evaluating the Efficacy and Clinical Utility of Empagliflozin-Linagliptin Combination Therapy in T2DM Management

By S. Sen, Akashkumar Singh, Ajoy Tewari, Embrace

Study in peopleInterventions

The paper

S. Sen, Akashkumar Singh, Ajoy Tewari, Embrace

Siliguri

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, poster 1491-P

doi.org/10.2337/db25-1491-p

Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk